Evidence map›Paper›PMID 29184163›Full record

ArticleScientific reports2017

All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion.

Xiao-Yan Fan, Peng-Yu Wang, Chao Zhang, Yu-Long Zhang, Yun Fu, Cong Zhang, Qiao-Xia Li, Jie-Na Zhou, Bao-En Shan, Dong-Wei He

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Retinoids as anti-cancer agents and their mechanisms of action.American journal of cancer research · 2022
    Review
  4. Dietary Habits in Japanese Patients with Alopecia Areata.Clinical, cosmetic and investigational dermatology · 2021
    Article
  5. Review
  6. Review
  7. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.International journal of molecular sciences · 2018
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiao-Yan FanDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, 050000, People's Republic of China.
Peng-Yu WangDepartment of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Chao ZhangResearch Center, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Yu-Long ZhangDepartment of Surgery, Number One Hospital of Shijiazhuang, Shijiazhuang, Hebei, 050000, People's Republic of China.
Yun FuResearch Center, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Cong ZhangDepartment of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Qiao-Xia LiDepartment of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Jie-Na ZhouDepartment of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Bao-En ShanResearch Center, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.
Dong-Wei HeDepartment of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China. chndongwhe@hotmail.com.
Hebei Medical University · CNFirst Hospital of Shijiazhuang · CNHebei General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine the growth inhibition capability of all-trans retinoic acid (ATRA) with cytokine-induced killer cells (CIKs), we evaluated their effects, alone and in combination, on human lung carcinoma A549 cells. CIKs treated with ATRA significantly inhibited cell growth. Additionally, CIK with ATRA synergistically inhibited migration and invasiveness, colony formation of A549 and NCI-H520 cells. Furthermore, analysis of apoptosis markers Bcl-2, Bax, Survivin and cleaved Caspase-3 showed that Bcl-2 and Survivin mRNA levels significantly decreased, and that Bax mRNA significantly increased, in the CIK + ATRA-treated cells, with corresponding effects on their respective proteins. The involved mechanisms may be associated with upregulated expression of MHC class I-Related Chain (MICA) and interleukin (IL)-2. These results suggest that administration of combined CIK and ATRA is a potentially novel treatment for lung carcinoma.

Indexed as

AnimalsApoptosisBiomarkersCell Line, TumorCell MovementCell ProliferationCytokine-Induced Killer CellsCytotoxicity, ImmunologicDisease Models, AnimalHistocompatibility Antigens Class IHumansImmunomodulationInterleukin-2MiceTretinoinBiomarkersHistocompatibility Antigens Class IInterleukin-2MHC class I-related chain ATretinoin

Identifiers

PMID29184163
PMCPMC5705634
OpenAlexW2768768021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.